Cellbion
308430
Company Profile
Business description
Cellbion is a radiopharmaceutical innovation engaged in the development and commercialization of radioligand therapies to address unmet medical needs, focusing on improving patient outcomes and advancing healthcare through groundbreaking research and cutting-edge technology. Its pipeline products targeted indications are Prostate Cancer radiotherapy, Solid Tumors Diagnosis, Multiple Cancer types, and Others.
Contact
103, Daehak-ro
6th Floor
Jongno-gu
Seoul03080
KORT: +82 27433311
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,369.30 | 4.70 | -0.06% |
| CAC 40 | 7,684.10 | 43.83 | -0.57% |
| DAX 40 | 23,074.40 | 270.14 | -1.16% |
| Dow JONES (US) | 41,218.83 | 98.60 | -0.24% |
| FTSE 100 | 8,595.85 | 0.50 | -0.01% |
| HKSE | 22,662.71 | 158.03 | 0.70% |
| NASDAQ | 17,844.24 | 133.49 | -0.74% |
| Nikkei 225 | 36,830.69 | 378.39 | 1.04% |
| NZX 50 Index | 12,421.09 | 0.16 | -0.00% |
| S&P 500 | 5,650.38 | 36.29 | -0.64% |
| S&P/ASX 200 | 8,151.40 | 6.40 | -0.08% |
| SSE Composite Index | 3,316.11 | 37.08 | 1.13% |